On November 3, 2020, Ever Supreme applied for the addition of the cell therapy technology of "Allogenic bone marrow-derived mesenchymal stem cells (BMSC) treating degenerative joint disease and knee cartilage defect", has been approved by the Taiwan FDA.

Ever Supreme is the contracted cell preparation site of China Medical University Hospital under the RGSCTT, and the hospital applied to Taiwan FDA for “Allogenic bone marrow-derived mesenchymal stem cells (BMSC) treating degenerative joint disease and knee cartilage defect”, and an official Taiwan FDA approval is received.

Permitted items in China Medical University Hospital the development plan is as followed:

(1)Excution of item: Allogenic bone marrow-derived mesenchymal stem cells (BMSC) transplant.
(2)Indications: Degenerative joint disease and knee cartilage defect.
(3)Cell preparation site: Cell Preparation Sites of Ever Supreme Bio Technology Co., LTD.
(4)Validity: Nov 2 2020 to April 30, 2023.

BACK